<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Medincell Sa — News on 6ix</title>
<link>https://6ix.com/company/medincell-sa</link>
<description>Latest news and press releases for Medincell Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 16:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/medincell-sa" rel="self" type="application/rss+xml" />
<item>
<title>Medincell to Host an Online R&D Day on Tuesday, May 12, 2026</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-to-host-an-online-randd-day-on-tuesday-may-12-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-to-host-an-online-randd-day-on-tuesday-may-12-2026</guid>
<pubDate>Thu, 16 Apr 2026 16:00:00 GMT</pubDate>
<description>MONTPELLIER, France, April 16, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL) will host an online R&D Day, held in English, on Tuesday, May 12, 2026, from 4:00 to 5:30 pm CEST (10:00 - 11:30 am ET / 7:00 - 8:30 am PT).</description>
</item>
<item>
<title>EIB Waives its Right to Cash Settlement on Medincell Warrants</title>
<link>https://6ix.com/company/medincell-sa/news/eib-waives-its-right-to-cash-settlement-on-medincell-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/eib-waives-its-right-to-cash-settlement-on-medincell-warrants</guid>
<pubDate>Thu, 26 Mar 2026 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, March 26, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that the European Investment Bank (EIB) has waived on March 26, 2026 the put option attached to approximately 780,000 warrants granted in connection with the €40 million financing agreement executed in 2022.</description>
</item>
<item>
<title>Medincell Announces Successful c. €48 Million Private Placement</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-announces-successful-c-euro48-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-announces-successful-c-euro48-million-private-placement</guid>
<pubDate>Fri, 06 Mar 2026 07:00:00 GMT</pubDate>
<description>MONTPELLIER, France, March 06, 2026--Regulatory News: This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or Japan</description>
</item>
<item>
<title>Medincell Launches a Private Placement for International Institutional Investors</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-launches-a-private-placement-for-international-institutional-investors</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-launches-a-private-placement-for-international-institutional-investors</guid>
<pubDate>Thu, 05 Mar 2026 16:35:00 GMT</pubDate>
<description>MONTPELLIER, France, March 05, 2026--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA</description>
</item>
<item>
<title>Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-to-participate-in-leerink-and-jefferies-miami-investor-conferences-march-8-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-to-participate-in-leerink-and-jefferies-miami-investor-conferences-march-8-11-2026</guid>
<pubDate>Wed, 04 Mar 2026 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, March 04, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation to the 2026 Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit in Miami, Florida, March 8 – 11, 2026.</description>
</item>
<item>
<title>Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-to-present-at-the-td-cowen-46th-annual-healthcare-conference-in-boston-march-2-4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-to-present-at-the-td-cowen-46th-annual-healthcare-conference-in-boston-march-2-4-2026</guid>
<pubDate>Tue, 24 Feb 2026 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, February 24, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced its participation at the TD Cowen 46th Annual Healthcare Conference, which will take place March 2-4, 2026 in Boston.</description>
</item>
<item>
<title>Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-us-food-and-drug-administration-fda-accepts-tevas-new-drug-application-nda-for-olanzapine-extended-release-injectable-suspension-tev-749-for-the-once-monthly-treatment-of-schizophrenia-in-adults</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-us-food-and-drug-administration-fda-accepts-tevas-new-drug-application-nda-for-olanzapine-extended-release-injectable-suspension-tev-749-for-the-once-monthly-treatment-of-schizophrenia-in-adults</guid>
<pubDate>Fri, 20 Feb 2026 20:37:00 GMT</pubDate>
<description>PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 20, 2026--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence an</description>
</item>
<item>
<title>Medincell’s ISS ESG Corporate Rating Upgraded</title>
<link>https://6ix.com/company/medincell-sa/news/medincells-iss-esg-corporate-rating-upgraded</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincells-iss-esg-corporate-rating-upgraded</guid>
<pubDate>Tue, 10 Feb 2026 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, February 10, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announces that ISS has upgraded the company’s ESG rating from C+ to B.</description>
</item>
<item>
<title>Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-uzedyr-net-sales-increased-from-dollar117m-in-2024-to-dollar191m-in-2025-63percent</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-uzedyr-net-sales-increased-from-dollar117m-in-2024-to-dollar191m-in-2025-63percent</guid>
<pubDate>Wed, 28 Jan 2026 13:04:00 GMT</pubDate>
<description>MONTPELLIER, France, January 28, 2026--Regulatory News: Medincell’s (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full‑year 2025 results:</description>
</item>
<item>
<title>Medincell: Half-year Liquidity Contract Statement</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-half-year-liquidity-contract-statement</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-half-year-liquidity-contract-statement</guid>
<pubDate>Tue, 20 Jan 2026 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, January 20, 2026--Regulatory News: Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at December 31, 2025:</description>
</item>
<item>
<title>Medincell: Publication of the 2026 Financial Calendar</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-publication-of-the-2026-financial-calendar</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-publication-of-the-2026-financial-calendar</guid>
<pubDate>Mon, 12 Jan 2026 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, January 12, 2026--Regulatory News: Medincell (Paris:MEDCL):</description>
</item>
<item>
<title>Medincell Publishes its Consolidated Half-Year Financial Results</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-publishes-its-consolidated-half-year-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-publishes-its-consolidated-half-year-financial-results</guid>
<pubDate>Tue, 09 Dec 2025 17:02:00 GMT</pubDate>
<description>MONTPELLIER, France, December 09, 2025--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): "We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leadin</description>
</item>
<item>
<title>Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults</title>
<link>https://6ix.com/company/medincell-sa/news/medincells-partner-teva-pharmaceuticals-announces-the-new-drug-application1-submission-to-us-fda-for-olanzapine-extended-release-injectable-suspension-tev-749-mdc-tjk-for-the-once-monthly-treatment-of-schizophrenia-in-adults</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincells-partner-teva-pharmaceuticals-announces-the-new-drug-application1-submission-to-us-fda-for-olanzapine-extended-release-injectable-suspension-tev-749-mdc-tjk-for-the-once-monthly-treatment-of-schizophrenia-in-adults</guid>
<pubDate>Tue, 09 Dec 2025 13:50:00 GMT</pubDate>
<description>MONTPELLIER, France, December 09, 2025--Regulatory News: Medincell (Paris:MEDCL):</description>
</item>
<item>
<title>Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-videoconference-and-publication-of-half-year-financial-results-tuesday-december-9-2025</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-videoconference-and-publication-of-half-year-financial-results-tuesday-december-9-2025</guid>
<pubDate>Mon, 01 Dec 2025 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, December 01, 2025--Regulatory News: Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025)</description>
</item>
<item>
<title>Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-management-to-present-at-the-8th-annual-evercore-healthcare-conference-and-at-the-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-management-to-present-at-the-8th-annual-evercore-healthcare-conference-and-at-the-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Thu, 27 Nov 2025 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, November 27, 2025--Regulatory News: Medincell (Paris:MEDCL):</description>
</item>
<item>
<title>Medincell Awarded New Grant to Fight Malaria</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-awarded-new-grant-to-fight-malaria</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-awarded-new-grant-to-fight-malaria</guid>
<pubDate>Mon, 24 Nov 2025 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, November 24, 2025--Regulatory News: Medincell (Paris:MEDCL):</description>
</item>
<item>
<title>Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025)</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-management-to-participate-in-fireside-chat-at-the-jefferies-london-healthcare-conference-2025-london-nov-17-20-2025</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-management-to-participate-in-fireside-chat-at-the-jefferies-london-healthcare-conference-2025-london-nov-17-20-2025</guid>
<pubDate>Thu, 13 Nov 2025 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, November 13, 2025--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell’s (Paris:MEDCL) corporate overview during a fireside chat at the Jefferies London Global Healthcare Conference on Tuesday, November 18, 2025, at 4:00 p.m. GMT (5:00 p.m. CET).</description>
</item>
<item>
<title>Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-appoints-dr-grace-kim-chief-strategy-officer-us-finance-to-advance-into-next-stage-of-us-capital-growth</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-appoints-dr-grace-kim-chief-strategy-officer-us-finance-to-advance-into-next-stage-of-us-capital-growth</guid>
<pubDate>Tue, 11 Nov 2025 07:00:00 GMT</pubDate>
<description>MONTPELLIER, France, November 11, 2025--Medincell, a clinical-stage pharmaceutical company pioneering long-acting injectable therapies, today announced the expanded role of Dr Grace Kim, Chief Strategy Officer, U.S. Finance.</description>
</item>
<item>
<title>Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-to-join-msci-world-small-cap-index-a-leading-global-benchmark</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-to-join-msci-world-small-cap-index-a-leading-global-benchmark</guid>
<pubDate>Mon, 10 Nov 2025 17:00:00 GMT</pubDate>
<description>MONTPELLIER, France, November 10, 2025--Medincell has been selected for inclusion in the Morgan Stanley Capital International (MSCI) World Small Cap Index, which encompasses the most liquid and high-performing small-cap companies across 23 developed markets.</description>
</item>
<item>
<title>Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)</title>
<link>https://6ix.com/company/medincell-sa/news/medincell-to-participate-in-the-ubs-global-healthcare-conference-palm-beach-and-the-stifel-healthcare-conference-new-york</link>
<guid isPermaLink="true">https://6ix.com/company/medincell-sa/news/medincell-to-participate-in-the-ubs-global-healthcare-conference-palm-beach-and-the-stifel-healthcare-conference-new-york</guid>
<pubDate>Thu, 06 Nov 2025 17:25:00 GMT</pubDate>
<description>MONTPELLIER, France, November 06, 2025--Regulatory News: Dr Grace Kim, Chief Strategy Officer, U.S. Finance, and Dr Richard Malamut, Chief Medical Officer, will speak on Medincell’s (Paris:MEDCL) value proposition, including recent developments and meet with investors at two upcoming investor conferences as follows:</description>
</item>
</channel>
</rss>